Microorganisms, Immunology & Vaccines

Overview

Microorganisms, immunology, and vaccines form a high-yield area in UPSC Prelims (Science & Technology) and GS3 Mains. Questions frequently test the differences among bacteria, viruses, fungi, and protozoa; the mechanism of vaccines; India's immunization programmes (Mission Indradhanush, UIP); and the growing crisis of antimicrobial resistance (AMR). A solid understanding of these topics also helps in answering current-affairs questions on pandemics, new vaccines, and One Health initiatives.

1. Types of Microorganisms

Microorganisms (microbes) are living organisms too small to be seen with the naked eye. They are broadly classified into four groups: bacteria, viruses, fungi, and protozoa.

1.1 Bacteria

• Cell type: Prokaryotic — lack a membrane-bound nucleus and membrane-bound organelles.
• Size: Typically 0.5--10 µm.
• Cell wall: Made of peptidoglycan. Gram staining classifies bacteria into Gram-positive (thick peptidoglycan layer, stains violet) and Gram-negative (thin peptidoglycan layer with outer lipid membrane, stains pink).
• Shapes:

• Reproduction: Primarily by binary fission (asexual). Genetic variation occurs through conjugation, transformation, and transduction.

1.2 Viruses

• Not truly living: Viruses are acellular — they lack cells, ribosomes, and metabolic machinery. They are metabolically inert outside a host cell and can only replicate inside living host cells.
• Structure: A core of nucleic acid (DNA or RNA, never both) surrounded by a protein coat called a capsid. Some viruses have an outer envelope derived from the host cell membrane.
• Classification by genetic material:
  • DNA viruses — Adenovirus, Herpesvirus, Poxvirus, Hepatitis B virus.
  • RNA viruses — Influenza virus, SARS-CoV-2, HIV, Dengue virus, Rabies virus, Hepatitis C virus.
• Size: Much smaller than bacteria — typically 20--300 nm.
• Bacteriophages are viruses that specifically infect bacteria.

1.3 Fungi

• Cell type: Eukaryotic — have a membrane-bound nucleus and organelles.
• Cell wall: Made of chitin (not peptidoglycan like bacteria).
• Modes of nutrition: Heterotrophic — mainly saprotrophic (decomposers of dead organic matter). Some are parasitic; some are symbiotic (e.g., mycorrhizae with plant roots, lichens with algae/cyanobacteria).
• Examples: Yeasts (unicellular), moulds (Penicillium, Aspergillus), mushrooms (multicellular).
• Reproduction: Spore formation (sexual and asexual), budding (yeasts), fragmentation.

1.4 Protozoa

• Cell type: Unicellular eukaryotes.
• Habitat: Mostly aquatic (freshwater, marine) or parasitic within hosts.
• Movement-based classification:
  • Amoeboids (pseudopodia) — Entamoeba histolytica (amoebic dysentery).
  • Flagellates (flagella) — Trypanosoma (sleeping sickness), Giardia.
  • Ciliates (cilia) — Paramecium.
  • Sporozoans (non-motile, spore-forming) — Plasmodium (malaria).

2. Beneficial Microorganisms

Not all microorganisms are harmful. Many play essential roles in food production, agriculture, medicine, and environmental cleanup.

2.1 Food & Fermentation

2.2 Nitrogen Fixation

• Rhizobium bacteria form a symbiotic association with roots of leguminous plants (peas, beans, groundnut, clover). They colonise root cells, forming root nodules, and convert atmospheric nitrogen (N2) into ammonia (NH3) using the enzyme nitrogenase. The plant supplies organic acids as a carbon source; in return, the bacteria supply usable nitrogen.
• Azotobacter and Clostridium are free-living nitrogen-fixing soil bacteria.
• Cyanobacteria (e.g., Anabaena, Nostoc) fix nitrogen in rice paddies and are important biofertilisers.

2.3 Antibiotics

• Alexander Fleming discovered penicillin in September 1928 when he observed that the mould Penicillium notatum (now reclassified as Penicillium rubens) inhibited the growth of Staphylococcus bacteria on a petri dish.
• Howard Florey and Ernst Boris Chain later developed methods for large-scale production of penicillin during World War II. All three shared the 1945 Nobel Prize in Physiology or Medicine.
• Antibiotics work only against bacteria, not viruses. Misuse of antibiotics against viral infections contributes to antimicrobial resistance.

2.4 Bioremediation

• Use of microorganisms to clean up environmental pollutants such as oil spills, heavy metals, and pesticides.
• Pseudomonas species are widely used in bioremediation of hydrocarbons and toxic compounds.
• Alcanivorax borkumensis is a naturally occurring marine bacterium that degrades oil hydrocarbons.

3. Infectious Diseases

Diseases caused by pathogenic microorganisms that can be transmitted from one person to another or through vectors.

3.1 Disease Summary Table

Exam Tip: Remember that antibiotics are effective ONLY against bacterial infections. Viral diseases require antivirals; fungal diseases need antifungals. This distinction is frequently tested in UPSC Prelims.

4. The Immune System

The immune system is the body's defence mechanism against pathogens. It has two main branches: innate (non-specific) and adaptive (specific) immunity.

4.1 Innate Immunity (Non-specific)

• Present from birth; does not require prior exposure to a pathogen.
• Provides the first and second lines of defence.
• First line: Physical barriers — skin, mucous membranes, stomach acid, saliva, tears (contain lysozyme).
• Second line: Cellular and chemical defences — phagocytes (neutrophils, macrophages), natural killer (NK) cells, inflammation, fever, complement system, interferons.
• Response is rapid (minutes to hours) but does not develop memory.

4.2 Adaptive Immunity (Specific)

• Develops after exposure to a specific antigen; takes days to activate on first encounter.
• Key feature: Immunological memory — faster, stronger response upon re-exposure (basis of vaccination).
• Two arms:
  • Humoral immunity (B-cell mediated) — B-lymphocytes produce antibodies (immunoglobulins) that circulate in blood and neutralise extracellular pathogens.
  • Cell-mediated immunity (T-cell mediated) — T-lymphocytes directly attack infected cells.

4.3 Key Immune Cells

4.4 Antibodies (Immunoglobulins)

Antibodies are Y-shaped proteins produced by B-cells. Each antibody has an antigen-binding site specific to one antigen. There are five classes:

Exam Tip: For UPSC, remember: IgG crosses the placenta, IgA is in secretions (breast milk protects newborns), IgM is the first responder, and IgE causes allergies.

4.5 Antigens vs Antibodies

• Antigen: Any substance (usually a protein on the surface of a pathogen) that triggers an immune response.
• Antibody: A protein produced by B-cells that specifically binds to an antigen and helps neutralise or destroy the pathogen.

5. Vaccines

A vaccine is a biological preparation that provides active acquired immunity to a specific infectious disease. Vaccines contain an agent resembling a disease-causing microorganism, which stimulates the immune system to recognise it as a threat, produce antibodies, and develop memory cells for future rapid response.

5.1 Types of Vaccines

5.2 India's COVID-19 Vaccines

6. India's Immunization Programme

6.1 Universal Immunization Programme (UIP)

• Launched: 1985 by the Government of India under the Ministry of Health and Family Welfare.
• Objective: Provide free vaccination to all children and pregnant women across the country.
• Coverage: One of the largest immunization programmes in the world, targeting approximately 2.67 crore newborns and 2.9 crore pregnant women annually.
• Diseases covered (currently 12): Tuberculosis, Diphtheria, Pertussis (Whooping Cough), Tetanus, Poliomyelitis, Measles, Hepatitis B, Rotaviral Gastroenteritis, Japanese Encephalitis (endemic areas), Rubella, Pneumonia caused by Haemophilus influenzae type B, and Pneumococcal diseases.

6.2 Key Vaccines in UIP Schedule

6.3 Mission Indradhanush

• Launched: 25 December 2014 by Union Health Minister J.P. Nadda.
• Objective: Achieve at least 90% full immunization coverage by reaching unvaccinated and partially vaccinated children and pregnant women, especially in underserved and hard-to-reach areas.
• Focus: Initially identified 201 high-focus districts (later expanded) with the highest number of partially immunised and unimmunised children.
• Impact: Between 2014 and 2018, India's annual immunisation growth rate rose to 6.7% — a significant jump from the earlier rate of about 1% per year.

6.4 Intensified Mission Indradhanush (IMI)

7. Antibiotic Resistance (AMR)

7.1 What is AMR?

Antimicrobial Resistance (AMR) occurs when microorganisms (bacteria, viruses, fungi, parasites) evolve to resist the drugs designed to kill them. When bacteria become resistant to antibiotics, infections become harder or impossible to treat, leading to longer illness, higher medical costs, and increased mortality.

7.2 Causes of AMR

• Overuse and misuse of antibiotics in humans (self-medication, incomplete courses).
• Over-the-counter availability of antibiotics without prescription (widespread in India).
• Overuse in agriculture and animal husbandry — antibiotics used as growth promoters in livestock and poultry.
• Poor infection control in hospitals (healthcare-associated infections).
• Inadequate sanitation and hygiene — leading to greater spread of resistant organisms.
• Lack of new antibiotic development — the antibiotic pipeline has slowed since the 1980s.

7.3 Superbugs

• Superbugs are strains of bacteria that have become resistant to multiple antibiotics.
• Examples: MRSA (Methicillin-Resistant Staphylococcus aureus), NDM-1-producing bacteria (New Delhi Metallo-beta-lactamase, first identified in 2009), extensively drug-resistant TB (XDR-TB).
• WHO classifies AMR as one of the top 10 global public health threats.

7.4 India's Response to AMR

National Action Plan on AMR (NAP-AMR) 2017--2021:

• Released in April 2017 by the Ministry of Health and Family Welfare, aligned with the WHO Global Action Plan on AMR.
• Six strategic priorities: (1) Improve awareness and understanding through communication and education; (2) Strengthen surveillance; (3) Reduce infection through prevention and control; (4) Optimise use of antimicrobials; (5) Promote research and innovation; (6) Strengthen India's leadership on AMR.
• Adopts the One Health approach — recognising that AMR must be tackled across human health, animal health, agriculture, fisheries, and the environment simultaneously.

ICMR AMR Surveillance Network (AMRSN):

• Established in 2013 by the Indian Council of Medical Research (ICMR).
• Monitors drug-resistant infection patterns across Indian hospitals.
• Expanded from 4 nodal centres initially to 21 centres, collecting over 4 lakh patient records.
• Publishes annual AMR surveillance reports; the data guides treatment guidelines and new drug development.

Other Measures:

• Red Line Campaign — antibiotics that should not be sold without prescription are marked with a red vertical line on the packaging.
• Schedule H1 — restricts over-the-counter sale of certain antibiotics; mandates prescription record-keeping by pharmacists.

7.5 One Health Approach

The One Health approach recognises the interconnection between the health of humans, animals, and the environment. AMR bacteria can transfer between animals and humans through the food chain, direct contact, or shared environments. Effective AMR control requires coordinated action across all three domains — this principle is central to both the WHO Global Action Plan and India's NAP-AMR.

8. UPSC Relevance

Key Areas for Prelims

• Classification of microorganisms (prokaryotic vs eukaryotic, DNA vs RNA viruses).
• Differences among types of vaccines (live attenuated vs inactivated vs subunit vs mRNA).
• Diseases and their causative agents (bacterial vs viral vs protozoan).
• India's immunization programmes — UIP, Mission Indradhanush, IMI phases.
• Antibody types and their functions (IgG crosses placenta, IgA in secretions).

Key Areas for Mains (GS3)

• AMR as a public health crisis — causes, consequences, and India's NAP-AMR.
• One Health approach and its relevance to AMR, zoonotic diseases, and pandemic preparedness.
• India's vaccination policy — successes of UIP and Mission Indradhanush, remaining challenges.
• Science & Technology questions on mRNA vaccines, COVID-19 vaccine development.
• Bioremediation and beneficial uses of microorganisms in agriculture and environment.

Frequently Tested Concepts

• Fleming discovered penicillin (1928); it is effective only against bacteria, not viruses.
• Vaccines work by stimulating the adaptive immune system to produce memory cells.
• Rhizobium fixes nitrogen in legume root nodules (symbiotic); Azotobacter is free-living.
• SARS-CoV-2 is an RNA virus; Hepatitis B is a DNA virus.
• UIP launched in 1985; now covers 12 diseases; Mission Indradhanush launched in December 2014.

Cross-paper relevance

• GS3 — General Science (primary) — Bacteria, viruses, fungi, protozoa; immune system; vaccines; Prelims factual domain (AMR, UIP, Mission Indradhanush)
• GS3 — Science & Technology — mRNA vaccine platforms, One Health approach, biodefence; ICMR's AMR National Action Plan 2.0 (2023–28)
• GS2 — Social Justice & Governance — Universal Immunization Programme (UIP), Mission Indradhanush; antibiotic stewardship as public policy; TRIPS and vaccine access
• Essay — "The war against microbes: science, society, and the antibiotic apocalypse"

Recent Developments (2024–2026)

India's AMR National Action Plan 2.0 — Antibiotic Resistance Response

India, in collaboration with WHO, developed the National Action Plan on Antimicrobial Resistance (AMR) 2.0 in 2024–25, with seven states endorsing state-level AMR containment plans. The AMR threat in India is severe — India is the world's largest consumer of antibiotics, and resistant strains of pathogens including drug-resistant TB (MDR-TB, XDR-TB), MRSA, and carbapenem-resistant Enterobacteriaceae (CRE) are rising. The ICMR's AMR surveillance network expanded to more hospitals for real-time data on resistance patterns.

UPSC angle: India's AMR Action Plan 2.0 is the most current public health policy development for this topic — directly relevant for both Prelims (AMR definitions) and Mains (policy responses to antibiotic resistance).

India's Universal Immunisation Programme — Expanded Coverage (2024)

India's Universal Immunisation Programme (UIP) achieved significant milestones: India became the world's largest vaccine producer, supplying 62% of global vaccine demand. In 2024, Serum Institute of India continued producing the world's largest volume of vaccines, and India's pharmaceutical bioeconomy reached USD 165.7 billion. WHO's 2024 India report noted progress on polio eradication maintenance and childhood immunisation coverage rates.

UPSC angle: India's vaccine manufacturing leadership and UIP expansion are key GS3 immunology-policy links — demonstrates applied science in public health.

NexCAR19 — India's First Indigenous CAR-T Cell Therapy (2024–25)

CAR-T (Chimeric Antigen Receptor T-cell) therapy is a form of immunotherapy in which a patient's own T-cells are genetically engineered to express a receptor that targets cancer cells. India achieved a landmark milestone with NexCAR19, developed by ImmunoACT (a spinoff of IIT Bombay and Tata Memorial Hospital), receiving regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) in October 2023 — making it India's first and the world's first humanised CAR-T cell therapy. By 2025, nearly 500 patients had been treated. NexCAR19 targets the CD19 antigen on B-cells and is approved for B-cell lymphomas and B-cell acute lymphoblastic leukaemia (B-ALL).

Key differentiator: the therapy is manufactured in approximately 20 days (versus 40+ days in global programmes) and costs significantly less (~$50,000) than Western equivalents (~$400,000+), making it a major advance in accessible cancer immunotherapy. PM Modi recognised NexCAR19 among the Top 3 Indian innovations at the ESTIC 2025 conclave.

UPSC angle: NexCAR19 — tests understanding of CAR-T cell therapy mechanism (adaptive immune system, T-cell engineering), India's biotech capabilities (IIT Bombay + Tata Memorial partnership), regulatory pathway (CDSCO approval), and the broader GS3 theme of translating science into accessible healthcare. Connects immunology (T-cells, CD19 receptor, B-cell cancers) to science and technology policy.

Vocabulary

Antibiotic

• Pronunciation: /ˌæntɪbaɪˈɒtɪk/
• Definition: A substance, originally produced by microorganisms such as fungi or bacteria, that can destroy or inhibit the growth of bacteria — ineffective against viruses.
• Root: Greek anti- = against + bios = life → biōtikos = fit for life; French antibiotique (1850s/1940s)
• Origin: From French antibiotique, from anti- (against) + Greek biōtikos (fit for life, from bios, life); first used in English in the 1850s, with modern medical usage from the 1940s following the development of penicillin.
• Part of Speech: noun; also adjective
• Word Family: antibiotic (n/adj), antibiotics (n pl), antibiosis (n), probiotic (n/adj), antibiotic-resistant (adj)
• Usage: The unregulated, over-the-counter sale of antibiotics in India has accelerated antimicrobial resistance, transforming a once-routine infection into a looming public-health crisis that demands stringent regulation under the National Action Plan.
• Synonyms: antibacterial, antimicrobial, bactericide, anti-infective, germicide
• Antonyms: probiotic, prebiotic
• Mnemonic: Anti (against) + bio (life): an antibiotic works "against the life" of harmful bacteria, killing them off.

Antigen

• Pronunciation: /ˈæntɪdʒən/
• Definition: Any substance — typically a protein on the surface of a pathogen — that is recognised as foreign by the immune system and triggers the production of antibodies.
• Root: French antigène: anti- (against/antibody) + Greek -genēs (born of, producer); first recorded 1905.
• Origin: From French antigène, from anti- (short for antibody) + -gène (producer, from Greek -genēs, born of); first recorded in 1905 in the Journal of the American Medical Association.
• Part of Speech: noun
• Word Family: antigen (n), antigens (n pl), antigenic (adj), antigenicity (n), antigenically (adv)
• Usage: Just as a healthy body mounts a calibrated defence only when a genuine antigen breaches its barriers, a mature democracy must reserve its coercive apparatus for real threats to public order, lest an overzealous state begin attacking the very citizenry it is meant to protect.
• Synonyms: immunogen, allergen, foreign body, pathogen, toxin, hapten
• Antonyms: antibody, immunoglobulin, antitoxin
• Mnemonic: Read it as ANTI + GEN = an "antibody generator": the intruder that triggers the body's defenders into action.

Probiotic

• Pronunciation: /ˌprəʊbaɪˈɒtɪk/
• Definition: A live microorganism — typically a bacterium such as Lactobacillus or Bifidobacterium — that, when consumed in adequate amounts, confers a health benefit on the host by supporting gut flora.
• Root: Latin pro- = for/in favour of; Greek biōtikos = pertaining to life (from bios = life); coined 1950s
• Origin: From pro- (for, in favour of, from Latin) + biotic (from Greek biōtikos, pertaining to life); first used in the 1950s as the conceptual opposite of antibiotic.

• Part of Speech: noun; adjective
• Word Family: probiotic (adj/n), probiotics (n plural), prebiotic (n/adj), antibiotic (n/adj)
• Usage: India's persistent burden of malnutrition and gut-related morbidity has prompted public-health experts to advocate the integration of affordable probiotic foods, such as traditional fermented preparations, into nutrition schemes as a low-cost, culturally rooted intervention.
• Synonyms: beneficial bacteria, gut-friendly culture, live culture, microbiotic, friendly flora
• Antonyms: antibiotic, antimicrobial, pathogen
• Mnemonic: PRO ("for") + BIOTIC ("life") = "for life" — the opposite of ANTI-biotic, which works against microbial life; probiotics are the friendly microbes that work for your life.

Key Terms

Monoclonal Antibodies

• Definition: Monoclonal antibodies (mAbs) are laboratory-produced antibody molecules that are all identical because they are derived from a single clone of B-lymphocyte cells, and are engineered to bind to one specific target (a single epitope) with high precision. They are used as targeted drugs and diagnostic reagents in cancer, autoimmune disease, infectious disease and beyond.
• Context: The breakthrough came in 1975 when Georges Köhler and César Milstein developed hybridoma technology — fusing antibody-producing B cells with immortal myeloma (cancer) cells to create a hybrid line that secretes a single antibody type indefinitely; the work earned a share of the 1984 Nobel Prize in Physiology or Medicine. The first therapeutic mAb, muromonab-CD3 (Orthoclone OKT3), was approved by the US FDA in 1986 to prevent organ-transplant rejection. Early mouse-derived antibodies provoked immune reactions in humans, driving the development of chimeric, humanised and fully human antibodies that are safer and more durable. India has become a significant manufacturing hub for biosimilar monoclonal antibodies such as trastuzumab, rituximab and adalimumab.
• UPSC Relevance: For Prelims, monoclonal antibodies are a high-yield Science & Technology topic — testable on the basic definition, hybridoma technology, the antibody-versus-vaccine distinction (passive vs active immunity), and applications in cancer therapy, COVID-19 treatment and diagnostic kits (including pregnancy tests and rapid antigen tests). For Mains GS3 (Science & Technology / biotechnology / health), it underpins answers on India's biopharma and biosimilar capability, affordable healthcare, and indigenisation of advanced therapeutics. This is a foundational biotech concept — no direct PYQ is cited here — that supports questions on the broader topic family of biotechnology, immunology and the pharmaceutical industry.

Vaccines and Immunity Types

• Definition: Immunity is the body's ability to resist a pathogen, classified as innate (inborn, non-specific) or adaptive (acquired, pathogen-specific); a vaccine is a biological preparation that trains the adaptive immune system to recognise and fight a specific pathogen, conferring active immunity without causing the disease.
• Context: The human immune system has two broad arms: innate immunity (present from birth — skin, mucous membranes, phagocytes) and adaptive immunity, which is pathogen-specific and generates immunological memory through B cells (antibody/humoral response) and T cells (cell-mediated response). Adaptive immunity may be active (the body makes its own antibodies after infection or vaccination) or passive (ready-made antibodies are received, as a baby gets from its mother or a patient from an antiserum). Vaccines exploit active immunity using weakened, killed, partial, or genetically-coded forms of a pathogen. India runs the world's largest such effort through the Universal Immunisation Programme (UIP).
• UPSC Relevance: This is a foundational Science & Technology / GS3 health concept that also surfaces in GS2 (government health schemes) and Prelims general science. UPSC typically tests the active-versus-passive distinction, classification of vaccine platforms (live attenuated, inactivated, toxoid, subunit, mRNA), the meaning of herd immunity, and matching schemes such as Mission Indradhanush and the UIP to the diseases they cover. No verified PYQ is cited here; treat it as a foundational concept underpinning recurring questions on immunisation, biotechnology, and public-health governance.

Antimicrobial Resistance

• Pronunciation: /ˌæntɪmaɪˈkrəʊbiəl rɪˈzɪstəns/
• Definition: The ability of microorganisms -- bacteria, viruses, fungi, and parasites -- to evolve and survive exposure to antimicrobial drugs (antibiotics, antivirals, antifungals, antiparasitics) that were previously effective against them, making infections progressively harder to treat and increasing the risk of disease spread, severe illness, and death. AMR occurs through natural evolutionary processes (random mutations, horizontal gene transfer between bacteria) but is dramatically accelerated by human misuse and overuse of antimicrobials. WHO estimates that by 2050, drug-resistant infections could cause 10 million deaths annually worldwide if unchecked, surpassing cancer as a cause of death.
• Context: Alexander Fleming, in his 1945 Nobel Prize lecture for the discovery of penicillin, presciently warned: "There is the danger that the ignorant man may easily underdose himself and by exposing his microbes to non-lethal quantities of the drug make them resistant." Key resistant pathogens (superbugs): MRSA (Methicillin-Resistant Staphylococcus aureus), NDM-1 (New Delhi Metallo-beta-lactamase 1, named after the city where it was first identified in 2008, confers resistance to nearly all beta-lactam antibiotics including carbapenems -- last-resort drugs), XDR-TB (Extensively Drug-Resistant Tuberculosis), and CRE (Carbapenem-Resistant Enterobacteriaceae). India is among the world's largest consumers of antibiotics, driven by over-the-counter availability, self-medication, irrational prescription, and heavy agricultural/veterinary use. India's NAP-AMR 1.0 was launched on 19 April 2017, aligned with the WHO Global Action Plan; NAP-AMR 2.0 was launched in 2024 with updated multi-sectoral strategies. The Red Line Campaign (2016) marks prescription-only antibiotics with a red line on packaging. Schedule H1 (2013) restricts sale of certain antibiotics without prescription.
• UPSC Relevance: GS3 (Science & Technology) and GS2 (Health). Prelims tests AMR definition, superbugs (MRSA, NDM-1 -- named after New Delhi), the distinction between antibiotics (target bacteria) and antivirals (target viruses -- antibiotics are useless against viral infections like flu and COVID), and Alexander Fleming (penicillin, 1928, Nobel Prize 1945). Mains frequently asks about AMR as a public health crisis -- causes (overuse, self-medication, over-the-counter availability without prescription, agricultural use in poultry/livestock), India's NAP-AMR (2017, updated 2024), ICMR AMR Surveillance Network, Red Line Campaign (2016), Schedule H1 restrictions, and the One Health approach to AMR (human + animal + environmental sectors). WHO classifies AMR as a top-10 global public health threat. Link to India's pharmaceutical industry (antibiotic production hub) and the tension between affordable medicine access and resistance prevention.

Herd Immunity

• Pronunciation: /hɜːd ɪˈmjuːnɪti/
• Definition: A form of indirect protection from an infectious disease that occurs when a sufficiently large proportion of a population becomes immune -- through vaccination or prior natural infection -- thereby reducing the probability of disease transmission to the remaining susceptible individuals who cannot be vaccinated (such as newborns, immunocompromised patients, and the elderly). The herd immunity threshold (HIT) is the minimum proportion of the population that must be immune to prevent sustained disease transmission; it depends on the disease's basic reproduction number (R0 -- the average number of people one infected person infects in a fully susceptible population).
• Context: The concept was first discussed in 1894 by American veterinary scientist Daniel Elmer Salmon in the context of livestock disease resistance; applied to human epidemiology from the 1920s and mathematically formalised in the 1970s. The threshold formula is HIT = 1 - (1/R0). Key thresholds: measles (R0 ~12-18, HIT ~92-95% -- one of the highest, requiring near-universal vaccination), polio (R0 ~5-7, HIT ~80-86%), diphtheria (R0 ~6-7, HIT ~83-86%), COVID-19 (R0 varied by variant, 2-8+). The concept gained unprecedented public attention during the COVID-19 pandemic, with debate about whether herd immunity could be achieved through natural infection alone (the "Great Barrington Declaration" approach, October 2020) versus vaccination (the dominant public health strategy). India's COVID-19 vaccination drive (220+ crore doses) aimed to achieve sufficient population immunity to reduce severe disease and mortality.
• UPSC Relevance: GS3 (Science & Technology) and GS2 (Health). Prelims may test the concept, the formula HIT = 1 - (1/R0), and disease-specific thresholds (measles ~95%, polio ~80-85%). Mains asks about herd immunity in the context of pandemic preparedness (COVID-19 experience), India's Universal Immunisation Programme (1985), Mission Indradhanush (targeting districts with <70% full immunisation), and vaccine hesitancy as a barrier to achieving herd immunity. Know that herd immunity protects the most vulnerable who CANNOT be vaccinated -- this ethical argument for universal vaccination is relevant for GS4. Also connects to India's role as "Pharmacy of the World" and Vaccine Maitri.